Ondine Biomedical raises $13.4M to fund global push, resumes trading
What's the deal? Ondine BiomedicalDealroom has a profile for this one. Try Dealroom → has raised £10 million (US$13.8M, roughly $13.4 million) in a placing and subscription, issuing 100,000,000 new shares at 10p each. The London-listed company (AIM: OBI) develops light-activated antimicrobial therapies to prevent and treat hospital infections.
Why now? The raise is more than execution capital — it is survival runway. At 30 June, Ondine held $5.3 million in cash and expected that to last only into mid-Q4 2026.
What's the endgame? Net proceeds will fund commercial traction, international growth, and regulatory work, extending the cash runway into early 2028. Management is targeting a US regulatory submission in mid-2027 for its Steriwave product.
Director backing: Chief executive officer Carolyn CrossDealroom has a profile for this one. Try Dealroom → subscribed for about £1.06 million (US$1.47M) of shares. Other directors collectively took roughly £0.11 million by applying amounts owed to them.
The fundraising, backed by existing shareholders, follows positive topline Phase 3 LANTERN results and early adoption steps, including hospital deployments in Canada and the UK and a pilot in Mexico. H1 revenue grew 23% to $1.25 million, though losses widened and the business remains cash-intensive. Trading in the shares, suspended for the raise, was restored at 7:30 BST.
What could go wrong? The capital finances execution rather than proving scale. Ondine must convert clinical results and pilots into meaningful commercial revenue before its new runway runs out.
The signal: For a small-cap medtech still burning cash, the raise sits in the lower band of deal sizes — but it buys Ondine the time to chase its US regulatory goal and turn trial data into sales.
Read more: investegate.co.uk
Image credit: Generated with Gemini
